Reaction
Therapeutic Procedure reporting signals
As of the last recalculation, Therapeutic Procedure appears in 1,355 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES (PRR 64.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 35 | 64.1 | 64.3 |
| Relugolix | 52 | 35.2 | 35.3 |
| Sodium Oxybate | 63 | 15.3 | 15.4 |
| Vibegron | 6 | 11.5 | 11.5 |
| Carboxymethylcellulose Sodium | 7 | 11.5 | 11.5 |
| Armodafinil | 14 | 10.3 | 10.3 |
| Bimekizumab | 11 | 8.0 | 8.0 |
| Patiromer | 7 | 7.8 | 7.8 |
| Macitentan | 34 | 7.7 | 7.7 |
| Cinacalcet Hydrochloride | 23 | 7.7 | 7.7 |
| Rivaroxaban | 84 | 6.5 | 6.5 |
| Riociguat | 13 | 6.2 | 6.2 |
| Ranolazine | 4 | 5.9 | 5.9 |
| Dofetilide | 4 | 5.9 | 5.9 |
| Cannabidiol | 7 | 4.6 | 4.6 |
| Ambrisentan | 35 | 4.4 | 4.4 |
| Esketamine Hydrochloride | 5 | 4.3 | 4.3 |
| Cenegermin-Bkbj | 3 | 3.8 | 3.8 |
| Pegfilgrastim | 24 | 3.8 | 3.8 |
| Natalizumab | 42 | 3.6 | 3.6 |
| Valbenazine | 4 | 2.4 | 2.4 |